New Application of Saligenyl Prodrugs Approach for the Delivery of Fosfoxacin Derivatives in Mycobacteria.
Fiche publication
Date publication
novembre 2023
Journal
Molecules (Basel, Switzerland)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GROSDEMANGE-BILLIARD Catherine
Tous les auteurs :
Munier M, Tritsch D, Lièvremont D, Rohmer M, Grosdemange-Billiard C
Lien Pubmed
Résumé
In this work, we implemented for the first time the Saligenyl prodrug strategy to increase the bioavailability of fosmidomycin phosphate analogs in bacteria. Here, we report the synthesis of 34 Saligenyl prodrugs of fosfoxacin and its derivatives. Among them, fifteen double prodrugs efficiently prevented the growth of the non-pathogenic, fast-growing .
Mots clés
Mycobacterium smegmatis, cycloSaligenyl prodrug, deoxyxylulose 5-phosphate reducto-isomerase, fosfoxacin, isoprenoid biosynthesis
Référence
Molecules. 2023 11 22;28(23):